
Azur Pharma has a 50 person CNS (Pysch) sales force. We are interested in acquiring or licensing US marketed products that we can use to leverage our current sales infrastructure.
Azur is also interested in developing its pipeline in the area of CNS mainly in the Pysch or Neurology fields. Our focus would be on late stage opportunities, i.e. Phase III or in registration.
We also have a preference for opportunities with lower clinical risk and are happy to look at projects such as reformulations of existing treatments.
Azur is interested in acquisitions or licensing. As a private company we retain flexibility on the structuring of transactions.